USA - NASDAQ:CNTG - NL0014040206 - Common Stock
The current stock price of CNTG is 0.325 USD. In the past month the price decreased by -33.52%. In the past year, price decreased by -68.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.53 | 100.19B | ||
| CI | THE CIGNA GROUP | 9.31 | 70.62B | ||
| LH | LABCORP HOLDINGS INC | 15.97 | 21.00B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.39 | 20.07B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 110.32 | 19.93B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.06B | ||
| HIMS | HIMS & HERS HEALTH INC | 75.98 | 9.27B | ||
| DVA | DAVITA INC | 13.4 | 8.84B | ||
| CHE | CHEMED CORP | 19.76 | 6.33B | ||
| RDNT | RADNET INC | 217.53 | 6.02B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 32.49 | 5.87B | ||
| OPCH | OPTION CARE HEALTH INC | 18.56 | 4.49B |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
CENTOGENE NV
Am Strande 7
Rostock MECKLENBURG-VORPOMMERN 18055 DE
CEO: Andrin Oswald
Employees: 493
Phone: 4938180113400
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
The current stock price of CNTG is 0.325 USD. The price decreased by -6.23% in the last trading session.
CNTG does not pay a dividend.
CNTG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.
CENTOGENE NV (CNTG) operates in the Health Care sector and the Health Care Providers & Services industry.
ChartMill assigns a fundamental rating of 1 / 10 to CNTG. CNTG has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CNTG reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -6.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.
For the next year, analysts expect an EPS growth of 39.38% and a revenue growth 22.37% for CNTG